NDRA: חוב לטווח קצר של החברה ENDRA Life Sciences

ENDRA Life Sciences (NDRA) manages the development of early detection systems for liver pathologies, demonstrating transparency regarding certification, although commercialization has been delayed. The stock price history reflects the asset's dynamics, where the indicator stands at 0.00. Management is currently updating its strategy while awaiting regulatory approval. Meanwhile, TAEUS technology makes steatosis diagnostics accessible and affordable, effectively equipping ultrasound scanners with MRI-level capabilities.

Short-term debts aggregate all obligations with a maturity of up to one year, allowing an investor to assess the current liquidity and transparency of the business's financial reporting. By analyzing the dynamics of short-term borrowed capital, one can identify underfunding risks during the commercialization phase of the TAEUS ultrasound system, where excessive debt load could weaken the market position of ENDRA Life Sciences (NDRA) until the software is widely implemented in clinics.